This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Taro Pharmaceutical Industries Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Taro Pharmaceutical Industries.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.6%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Dec 12

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Aug 16

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Jun 02

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Feb 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Jan 24

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Oct 28

Taro Pharmaceutical hits 52-week low; down 28% YTD

Aug 15

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Jul 27

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Jul 14

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Aug 03

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Jan 26

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Taro Pharmaceutical Industries non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NYSE:TARO - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2024	629	54	70	125	N/A
12/31/2023	611	46	88	143	N/A
9/30/2023	593	33	97	125	N/A
6/30/2023	575	21	75	98	N/A
3/31/2023	573	25	14	32	N/A
12/31/2022	570	46	2	16	N/A
9/30/2022	569	65	-198	-188	N/A
6/30/2022	571	91	-271	-261	N/A
3/31/2022	561	58	-171	-159	N/A
12/31/2021	566	1	-161	-149	N/A
9/30/2021	568	8	72	86	N/A
6/30/2021	578	29	10	26	N/A
3/31/2021	549	-387	29	46	N/A
12/31/2020	576	-303	22	44	N/A
9/30/2020	583	-268	76	100	N/A
6/30/2020	601	-257	228	253	N/A
3/31/2020	645	244	243	272	N/A
12/31/2019	650	248	252	281	N/A
9/30/2019	678	274	258	289	N/A
6/30/2019	677	281	291	324	N/A
3/31/2019	670	282	293	324	N/A
12/31/2018	665	310	331	363	N/A
9/30/2018	644	234	313	343	N/A
6/30/2018	655	224	304	333	N/A
3/31/2018	662	211	294	324	N/A
12/31/2017	683	208	N/A	343	N/A
9/30/2017	748	330	N/A	384	N/A
6/30/2017	807	401	N/A	454	N/A
3/31/2017	879	457	N/A	438	N/A
12/31/2016	948	489	N/A	476	N/A
9/30/2016	986	538	N/A	458	N/A
6/30/2016	969	547	N/A	383	N/A
3/31/2016	951	541	N/A	395	N/A
12/31/2015	930	579	N/A	454	N/A
9/30/2015	909	532	N/A	440	N/A
6/30/2015	948	542	N/A	439	N/A
3/31/2015	863	485	N/A	407	N/A
12/31/2014	806	422	N/A	277	N/A
9/30/2014	782	395	N/A	294	N/A
6/30/2014	736	348	N/A	329	N/A
3/31/2014	759	361	N/A	358	N/A
12/31/2013	737	321	N/A	349	N/A
9/30/2013	709	294	N/A	327	N/A
6/30/2013	665	263	N/A	294	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if TARO's forecast earnings growth is above the savings rate (2.4%).

Guadagni vs Mercato: Insufficient data to determine if TARO's earnings are forecast to grow faster than the US market

Guadagni ad alta crescita: Insufficient data to determine if TARO's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if TARO's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: Insufficient data to determine if TARO's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Taro Pharmaceutical Industries Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to US$54.00

Consensus EPS estimates fall by 12%

Consensus forecasts updated

Price target decreased to US$75.00

Consensus EPS estimates fall by 25%

Price target lowered to US$82.00

Recent updates

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately

Taro Pharmaceutical Shareholders Approve Merger with Sun Pharma and Taro Pharmaceutical Shares to Be De-Listed from the NYSE

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2024 Results on May 20, 2024

Taro Pharmaceutical Industries Ltd. to Report Q3, 2024 Results on Jan 25, 2024

Taro Pharmaceutical Industries to Delist from NYSE

Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 28, 2023

Taro Pharmaceutical Industries Ltd. to Report Q2, 2024 Results on Oct 26, 2023

Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Taro Pharmaceutical Industries Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Taro Pharmaceutical Industries Ltd. Appoints Mr. Oded H. Sarig, Ph. D, to Serve as Director

Taro Pharmaceutical Industries Ltd. Announces Resignation of Dov Pekelman from the Board of Directors

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Taro Pharmaceutical Industries to be Delisted from NYSE

Full year 2023 earnings: EPS misses analyst expectations

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2023 Results on May 23, 2023

Investor sentiment improves as stock rises 22%

Investor sentiment deteriorates as stock falls 16%

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Taro Pharmaceutical Industries Ltd. to Report Q3, 2023 Results on Jan 24, 2023

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 29, 2022

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Taro Pharmaceutical Industries Ltd. to Report Q2, 2023 Results on Oct 27, 2022

Price target decreased to US$54.00

Taro Pharmaceutical hits 52-week low; down 28% YTD

Taro Pharmaceutical Industries Ltd. to Report Q1, 2023 Results on Jul 27, 2022

Full year 2022 earnings: EPS misses analyst expectations

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Consensus EPS estimates fall by 12%

Full year 2022 earnings: EPS misses analyst expectations

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2022 Results on May 26, 2022

Less than half of directors are independent

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) completed the acquisition of Alchemee LLC from Galderma Holding SA.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) entered into a definitive agreement to acquire Alchemee LLC from Galderma Holding SA.

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Taro Pharmaceutical Industries Ltd. Announces Impairment for the Third Quarter Ended December 31, 2021

Price target decreased to US$75.00

Consensus EPS estimates fall by 25%

Second quarter 2022 earnings released: EPS US$0.62 (vs US$1.18 in 2Q 2021)

VP, CFO & Chief Accounting Officer Daphne Huang has left the company

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

First quarter 2022 earnings released: US$0.50 loss per share (vs US$11.37 loss in 1Q 2021)

Full year 2021 earnings released: US$10.12 loss per share (vs US$6.35 profit in FY 2020)

Full year 2021 earnings released: US$10.12 loss per share (vs US$6.35 profit in FY 2020)

New 90-day high: US$79.95

Third quarter 2021 earnings released: EPS US$0.86 (vs US$1.76 in 3Q 2020)

Revenue and earnings miss expectations

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Taro Pharmaceutical Industries Ltd. to Report Q3, 2021 Results on Jan 27, 2021

New 90-day high: US$72.80

New 90-day high: US$72.47

New 90-day high: US$64.76

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 14, 2020

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS US$1.18

New 90-day low: US$54.40

Taro Launches Specialty Generic Deferiprone Tablets, 500Mg in the U.S

New 90-day low - US$57.42

New 90-day low - US$62.26

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) completed the acquisition of Aquinox Pharmaceuticals Inc. (Canada), Inc. from Neoleukin Therapeutics, Inc.